An open up-label research was carried out in 2016 in the UK to research the feasibility, safety and efficacy of psilocybin in managing sufferers with unipolar treatment-resistant depression with promising success; although the examine was smaller and included only twelve people, seven of Those people sufferers satisfied official standards for remis